Medisin

Følg
Medical researchers at University of Calgary reviewing glioblastoma scans alongside niacin supplements for a clinical trial illustration.
Bilde generert av AI

Early University of Calgary trial tests high-dose niacin as add-on treatment for glioblastoma

Rapportert av AI Bilde generert av AI Faktasjekket

Researchers at the University of Calgary are studying whether high doses of vitamin B3 (niacin) can improve outcomes for patients with newly diagnosed glioblastoma when added to standard treatment. An interim analysis of 24 patients found a higher-than-expected six‑month progression‑free survival rate, though investigators stress the results are preliminary and require ongoing safety monitoring.

A study has identified how an existing medication could improve immunotherapy outcomes for fibrolamellar carcinoma. The rare liver cancer currently has no cure and often spreads before detection. Researchers demonstrated the approach using patient tumor samples.

Rapportert av AI Faktasjekket

A Newcastle University-led screening study of nearly 300 adults in northern Britain found persistently high rates of low vitamin D in older people and adults from minoritized ethnic groups, with little evidence that summer months substantially improved levels.

Researchers at the University of California, Riverside have proposed that amyloid beta disrupts tau protein function inside neurons, potentially triggering Alzheimer's disease. The findings challenge the focus on external plaques as the primary cause.

Rapportert av AI

Two existing medications cooled core body temperature in animals after stroke and reduced brain damage. A small human trial showed limited effect due to slow delivery. Researchers are now planning a follow-up study with faster infusions.

Det medisinsktekniske selskapet SpectraCure i Lund gjennomfører en fortrinnsrettsemisjon som vil tilføre 34,2 millioner kroner dersom den blir fulltegnet. Emisjonen skal finansiere kliniske studier og regulatoriske søknader. Aksjen falt mer enn 20 prosent på mandag.

Rapportert av AI Faktasjekket

Adults with obesity who began taking GLP-1 receptor agonist medications showed declines in Fitbit-measured physical activity after starting treatment, according to a retrospective study presented Saturday at ENDO 2026, the Endocrine Society’s annual meeting in Chicago.

 

 

 

Dette nettstedet bruker informasjonskapsler

Vi bruker informasjonskapsler for analyse for å forbedre nettstedet vårt. Les vår personvernerklæring for mer informasjon.
Avvis